Xiaodong YangSan Jose, CA

7939637, May 10, 2011

Dec 8, 2006

11/608705

Olivia Raeber - Redwood City CA, US
Xiaodong Yang - Palo Alto CA, US
Susan Ann Cartlidge - Macclesfield, GB
David William Tonge - Macclesfield, GB

MedImmune Limited - Cambridge

A61K 39/395
C07H 21/04
C12P 21/06
C07K 16/26

5303871, 4241411, 4241451, 435335, 5303881, 53038823

Binding proteins, such as antibodies directed to IGF-II with cross-reactivity to IGF-I and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the IGF-II with cross-reactivity to IGF-I are disclosed. Also discussed are nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3.

2011004, Feb 24, 2011

Jun 20, 2008

12/665819

Xiaodong Yang - Palo Alto CA, US
Frank Y. Xie - Germantown MD, US
Yijia Liu - Gaithersburg MD, US
Ying Liu - Palo Alto CA, US

Intradigm Corporation - Palo Alto CA

A61K 38/02
C07H 21/02
A61K 31/713
C12N 5/071
A61P 35/00

514 193, 536 245, 514 44 A, 435375

The present invention provides nucleic acid molecules that inhibit EGFR expression. Methods of using the nucleic acid molecules are also provided.

2011020, Aug 18, 2011

Apr 1, 2011

13/078480

Olivia Raeber - Redwood city CA, US
Xiaodong Yang - Palo Alto CA, US
Susan Ann Cartlidge - Cheshire, GB
David William Tonge - Cheshire, GB

MedImmune Limited - Cambridge

A61K 39/395
A61P 35/00

4241421, 4241581

Binding proteins, such as antibodies directed to IGF-II with cross-reactivity to IGF-I and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the IGF-II with cross-reactivity to IGF-I are disclosed. Also discussed are nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3.

2022040, Dec 22, 2022

Jan 19, 2022

17/579408

- Santa Clara CA, US
Xin Wang - Santa Clara CA, US
Xiaolu Yang - Santa Clara CA, US
Zehui Li - Santa Clara CA, US
Shuang Zhou - Santa Clara CA, US
Xiaodong Yang - Santa Clara CA, US

A23L 33/175
A61P 3/10
A61P 3/04
A61P 3/06

The present disclosure provides compositions and methods for treating cancer with nutritionally modified diets and/or dialysis treatment, such as through amino acid depletion of one or more nonessential amino acids. In some aspects, the present disclosure provides compositions and methods for treating obesity with such modified diets and/or dialysis treatment. Furthermore, in some aspects, the present disclosure provides compositions and methods for treating renal disease with such modified diets and/or dialysis treatment.

2022037, Nov 24, 2022

Sep 11, 2020

17/761424

- San Carlos CA, US
Sushma KRISHNAN - San Carlos CA, US
Christine TAN - San Carlos CA, US
Rena BAHJAT - San Carlos CA, US
Xiaodong YANG - San Carlos CA, US
Ryan ALVARADO - San Carlos CA, US

C07K 16/28

Provided are anti-tumor necrosis factor receptor 2 (TNFR2) antibodies and related compositions, which may be used in any of a variety of therapeutic or diagnostic methods, including the treatment or diagnosis of oncological diseases, inflammatory and/or autoimmune diseases, and others. In some embodiments, the isolated antibody, or antigen-binding fragment thereof, does not substantially bind to TNFR1, herpesvirus entry mediator (HVEM), CD40, death receptor 6 (DR6), and/or osteoprotegerin (OPG).

2021013, May 13, 2021

Jun 22, 2018

16/623601

- San Carlos CA, US
Christine TAN - San Carlos CA, US
Pia BJÖRCK - San Carlos CA, US
Xiaodong YANG - San Carlos CA, US

C07K 16/28
A61K 35/17
C07K 14/54

Provided are anti-VISTA monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of a variety of inflammatory, oncological, and infectious diseases.

2021013, May 13, 2021

Jun 23, 2020

16/909156

- San Carlos CA, US
Erin L. Filbert - San Carlos CA, US
Xiaodong Yang - San Carlos CA, US

C07K 16/28
A61P 35/00
A61K 39/395
A61K 45/06

The present invention provides methods that utilize an agonistic anti-CD40 antibody in combination with another immune modulating agent, such as an immune checkpoint inhibitor (e.g., PD-1 inhibitor, PD-L1 inhibitor, CTLA-4 inhibitor, or VISTA inhibitor) and/or an innate immunity activator (e.g., TLR-4 agonist) and related compositions. The high affinity anti-CD40 antibody combinations may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases. In particular, combinations of the anti-CD40 antibody APX005M with an immune checkpoint inhibitor or an innate immunity activator are disclosed.

2021005, Feb 25, 2021

Aug 21, 2020

17/000048

- Santa Clara CA, US
Tanmay Gupta - Santa Clara CA, US
Xiaodong Yang - Santa Clara CA, US
Jan Kautz - Santa Clara CA, US

G06K 9/62
G06N 3/08

The disclosure provides a framework or system for learning visual representation using a large set of image/text pairs. The disclosure provides, for example, a method of visual representation learning, a joint representation learning system, and an artificial intelligence (AI) system that employs one or more of the trained models from the method or system. The AI system can be used, for example, in autonomous or semi-autonomous vehicles. In one example, the method of visual representation learning includes: (1) receiving a set of image embeddings from an image representation model and a set of text embeddings from a text representation model, and (2) training, employing mutual information, a critic function by learning relationships between the set of image embeddings and the set of text embeddings.